Login to Your Account

Top-Line Data Coming Soon

Biogen's Cardio Exit Leaves Cardiokine Solo on Lixivaptan

By Jennifer Boggs

Friday, November 5, 2010
The dramatic restructuring plan disclosed earlier this week by Biogen Idec Inc. has the Weston, Mass.-based firm clearing out of the cardiovascular space altogether, a move that leaves Cardiokine Inc. flying solo on hyponatremia drug lixivaptan. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription